Breast
Cancer Trials
Red
color connotes government-sponsored trials.
Green color connotes pharmaceutical-sponsored
trials.
B35 - Patients with DCIS (ductal carcinoma in situ) without invasive breast cancer are randomly assigned to
Tamoxifen
or
Arimidex (aromatase inhibitor).
Both of these agents have demonstrated efficacy in the prevention of breast cancer in high risk women.
S0221 -
Postmenopausal patients with metastatic breast cancer who have not received chemotherapy or hormonal therapy for metastatic disease are eligible for this trial.
Patients are randomly assigned to either:
1-
Arimidex (a drug that depletes the body of estrogen)
-or-
2-
Arimidex + Faslodex (a drug that decreases the response of tumors to estrogen)
S0226 - Women with lymph node positive or high risk lymph node negative breast cancer after surgery are eligible.
Patients are randomly allocated to receive one of four treatment programs:
1-Adriamycin/Cytoxan(AC) every 2 weeks for 6 cycles followed by high dose Taxol every 2 weeks for 6 cycles
2-AC evry 2 weeks for 6 cycles followed by low dose Taxol weekly for 12 weeks
3-Weekly Adriamycin and daily oral cytoxan for 15 weeks folowed by high dose Taxol every 2 weeks for 6 cycles
4-Weekly Adriamycin and daily oral Cytoxan for 15 weeks followed by weekly low dose Taxol for 12 weeks
S0307 -
All patients with recently diagnosed breast cancer who will require either hormonal therapy or chemotherapy before or after surgery are eligible for this trial.
Patients are randomly assigned to one of the three following treatment arms:
1-Zometa (an intravenous drug that promotes bone growth)
2-Clodronate (an oral drug that promotes bone growth)
3-Ibandronate (an oral drug that promotes bone growth)
All three of these drugs belong to a class that has been shown to reduce the spread of breast cancer in some studies. These are not chemotherapy drugs.
SOFT - SOFT is an international trial for pre-menopausal women, who have recently had surgery and whose tumors express the estrogen receptor.The trial compares treatment with one of three plans to deprive the cancer cells of hormonal stimulation:
1-Tamoxifen
2-Ovarian suppression (medicines to stop ovarian function) plus Tamoxifen
3-Ovarian suppression plus Exemestane
Patients are eligible whether or not they are treated with chemotherapy or radiation therapy.
C40101– Eligible patients are women who have recently had surgery and have no involvement of the lymph nodes or only 1-3 involved nodes.
Patients are randomized
(randomly allocated) to
1-Adriamycin/Cytoxan
every 2 weeks for 4 treatments
or
2-Adriamycin/Cytoxan every 2 weeks for 6 treatments
or
3-Taxol every 2 weeks for 4 treatments
or
4-Taxol every 2 weeks for 6 treatments
C49907
– Women 65 or older who whave recently had surgery and are
considered at high risk of recurrence. Patients are randomly allocated
to:
1-Chemotherapy
by intravenous injection and infusion
or
2-Oral chemotherapy with Capecitabine
NMA.27 – Women who have stopped having menses whose tumors make the estrogen receptor (2/3 of patients) are eligible. These patients will have had recent surgery without spread of cancer outside of breast or lymph nodes. Patients are randomly allocated to:
1-Exemestane
or
2-Anastrozole (these drugs are a new class of oral agents that are effective in patients with advanced breast cancer)
USO 04070
– Patients with metastatic breast cancer who have received no chemotherapy or one course of chemotherapy for metastatic disease are eligible for this trial.
Patients are randomly assigned to chemotherapy with CPT-11 and Carboplatin (weekly for 2/3 weeks) with or without weekly erbitux (erbitux is an antibody that interferes with a protein that promotes tumor growth)
CANCER PREVENTION
MAP3 – International breast cancer prevention trial. Postmenopausal women at increased risk of developing invasive breast cancer (family history, personal history of DCIS,atypical hyperplasia) are eligible for this important trial. Patients are randomly assigned to treatment with : Exemestane or Placebo
Red
color connotes government-sponsored trials.
Green color connotes pharmaceutical-sponsored
trials.
<Back
to Top>
|
